MECHANISM OF DISEASE
IN RMS PROGRESSION, THERE'S AN INVERSE RELATIONSHIP BETWEEN INFLAMMATION AND NEURODEGENERATION1
From inflammation to neurodegeneration, progressing patients
will have different needs2,3
From inflammation to neurodegeneration, progressing patients will have different needs2,3


LOOK BEYOND RELAPSES
Progressing RMS patients typically have fewer relapses or diminishing MRI activity.
So, when it comes to early identification of progression in your patients—look further.
Monitor for physical and cognitive changes using the EDSS4-6
LOOK BEYOND RELAPSES
Progressing RMS patients typically have fewer relapses or diminishing MRI activity. So, when it comes to early identification of progression in your patients—look further. Monitor for physical and cognitive changes using the EDSS4-6
MECHANISM OF ACTION
THE DUAL MOA OF MAYZENT® TARGETS S1P1,5—2 KEY
RECEPTORS THOUGHT TO PLAY A ROLE IN RMS
INFLAMMATION AND NEURODEGENERATION7-11
THE DUAL MOA OF MAYZENT® TARGETS S1P1,5—2 KEY RECEPTORS THOUGHT TO PLAY A ROLE IN RMS INFLAMMATION AND NEURODEGENERATION7-11
MAYZENT is an oral, selective S1P receptor modulator for progressing
patients along the RMS continuum7
-
Works in the periphery to limit active lymphocytes from leaving the lymph nodes,
which may reduce lymphocyte migration into the CNS7 -
Lymphocytes are stored, not destroyed in the lymph nodes; upon discontinuation,
blood lymphocyte counts rapidly recover within 10 days7*†
-
Works in the periphery to limit active lymphocytes from leaving the lymph nodes, which may reduce lymphocyte migration into the CNS7
-
Lymphocytes are stored, not destroyed in the lymph nodes; upon discontinuation, blood lymphocyte counts rapidly recover within 10 days7*†
THE PROPOSED MOA OF MAYZENT


The mechanism by which siponimod exerts therapeutic effects on MS is unknown but may involve reduction of lymphocytes in the CNS.7
GET PATIENTS STARTED ON MAYZENT®
CNS=central nervous system; EDSS=Expanded Disability Status Scale; MOA=mechanism of action; MOD=mechanism of disease; MRI=magnetic resonance imaging; MS=multiple sclerosis; RMS=relapsing MS; RRMS=relapsing-remitting MS; S1P=sphingosine 1-phosphate.
*In 90% of patients.7
†After stopping MAYZENT treatment, residual lowering of peripheral lymphocyte count may persist for up to 3-4 weeks after the last dose.7
‡Based on animal studies.7
References: 1. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52(1):61-76. 2. Bradl M, Lassmann H. Progressive multiple sclerosis. Semin Immunopathol. 2009;31(4):455-465. 3. Types of MS. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/What-is-MS/Types-of-MS. Accessed March 3, 2020. 4. Fox RJ, Cohen JA. Multiple sclerosis: The importance of early recognition and treatment. Cleve Clin J Med. 2001;68(2):157-171. 5. Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet. 2017;389(10076):1357-1366. 6. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. 7. Mayzent [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2019. 8. O’Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1/S1PR5 drug BAF312 (siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016;13:31. 9. Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035-1037. 10. Mannioui A, Vauzanges Q, Fini JB, et al. The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination. Mult Scler. 2018;24(11):1421-1432. 11. Choi JW, Chun J. Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta. 2013;1831(1):20-32. 12. Briard E, Rudolph B, Desravaud S, Krauser JA, Auberson YP. MS565: A SPECT Tracer for Evaluating the Brain Penetration of BAF312 (Siponimod). ChemMedChem. 2015;10(6):1008-1018. 13. Behrangi N, Fischbach F, Kipp M. Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action. Cells. 2019;8(24):1-11.